Eur Respir J 1998; 12: 1271-1277
Copyright © ERS Journals Ltd 1998
Effect of low-dose acetazolamide on the ventilatory CO2 response during hypoxia in the anaesthetized cat
M Wagenaar,
L Teppema,
A Berkenbosch,
C Olievier,
and
H Folgering
Acetazolamide, a carbonic anhydrase inhibitor, is used in patients with chronic obstructive pulmonary diseases and central sleep apnoea syndrome and in the prevention and treatment of the symptoms of acute mountain sickness. In these patients, the drug increases minute ventilation (V'E), resulting in an improvement in arterial oxygen saturation. However, the mechanism by which it stimulates ventilation is still under debate. Since hypoxaemia is a frequently observed phenomenon in these patients, the effect of 4 mg x kg(-1) acetazolamide (i.v.) on the ventilatory response to hypercapnia during hypoxaemia (arterial oxygen tension (Pa,O2)=6.8+/-0.8 kPa, mean+/-SD) was investigated in seven anaesthetized cats. The dynamic end-tidal forcing (DEF) technique was used, enabling the relative contributions of the peripheral and central chemoreflex loops to the ventilatory response to a step change in end-tidal carbon dioxide tension, (PET,CO2) to be separated. Acetazolamide reduced the CO2 sensitivities of the peripheral (Sp) and central (Sc) chemoreflex loops from 0.22+/-0.08 to 0.11+/-0.03 L x min(-1) x kPa(-1) (mean+/-SD) (p<0.01) and from 0.74+/-0.32 to 0.40+/-0.10 L x min(-1) x kPa(-1) (p<0.01), respectively. The apnoeic threshold B (x-intercept of the ventilatory CO2 response curve) decreased from 2.88+/-0.97 to 0.95+/-0.92 kPa (p<0.01). The net result was a stimulation of ventilation at PET,CO2 <5 kPa. The effect of acetazolamide is possibly due to a direct effect on the peripheral chemoreceptors as well as to an effect on the cerebral blood flow regulation. Possible clinical implications of these results are discussed.
This article has been cited by other articles:

|
 |

|
 |
 
M. Yamauchi, J. Dostal, and K. P. Strohl
Acetazolamide protects against posthypoxic unstable breathing in the C57BL/6J mouse
J Appl Physiol,
October 1, 2007;
103(4):
1263 - 1268.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Jonk, I. P. van den Berg, I. M. Olfert, D. W. Wray, T. Arai, S. R. Hopkins, and P. D. Wagner
Effect of acetazolamide on pulmonary and muscle gas exchange during normoxic and hypoxic exercise
J. Physiol.,
March 15, 2007;
579(3):
909 - 921.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Wagenaar, P. Vos, Y. Heijdra, L. Teppema, and H. Folgering
Comparison of Acetazolamide and Medroxyprogesterone as Respiratory Stimulants in Hypercapnic Patients With COPD
Chest,
May 1, 2003;
123(5):
1450 - 1459.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G P Bootsma, Y Heijdra, and M Wagenaar
Chronic respiratory failure
Thorax,
March 1, 2003;
58(3):
281 - 281.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Wagenaar, P. Je Vos, Y.F. Heijdra, L.J. Teppema, and H.T.M. Folgering
Combined treatment with acetazolamide and medroxyprogesterone in chronic obstructive pulmonary disease patients
Eur. Respir. J.,
November 1, 2002;
20(5):
1130 - 1137.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J Teppema, A. Dahan, and C. N Olievier
Low-dose acetazolamide reduces CO2-O2 stimulus interaction within the peripheral chemoreceptors in the anaesthetised cat
J. Physiol.,
November 15, 2001;
537(1):
221 - 229.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the European Respiratory Society.
|